Abstract:IntroductionTreatments for advanced lung cancer in patients with a poor performance status are limited. Such patients (PS 3–4) may not be suitable for chemotherapy for NSCLC, but may benefit from chemotherapy if SCLC is confirmed or treatment with an EGFR-TKI if an EGFR sensitising mutation (EGFR-sm) is detected. Estimates of the likelihood of detecting these two subtypes will enable patients to make informed decisions about undergoing biopsy confirmation.AimTo analyse patient factors that affect the frequency… Show more
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.